© The Author 2006. Published by Oxford University Press.
EDITORIAL |
BRCA Mutation Frequency and Penetrance: New Data, Old Debate
Correspondence to: Kenneth Offit, MD, MPH, Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: offitk{at}mskcc.org).
More than a decade after the discovery of the BRCA1 and BRCA2 genes, a consensus has yet to emerge regarding the frequency and precise magnitude and spectrum of cancer risks for individuals carrying mutations of these genes. Although these questions constitute a topic of heated debate among cancer epidemiologists (1–9), they are also of clinical concern to women and men considering BRCA testing and the various options, including preventive surgeries, if such testing produces a positive finding (10,11). The study by Risch et al. (12) not only helps to settle some of these issues but also adds interesting new data to an already extensive literature.
Expanding their previous analysis (13) of 649 case patients to 1171 case patients with epithelial ovarian cancer and 8680 first-degree relatives ascertained in Ontario for a 5-year period, Risch et al. analyzed DNA samples for BRCA mutations and documented self-reported family history information. When a subset of 977 case patients with invasive ovarian cancer was analyzed, BRCA mutations were found in 129 (13.2%). Among BRCA1 and BRCA2 mutation carriers, corresponding risks for breast cancer to age 80 years were 90% and 41% and corresponding risks for ovarian cancer 24% and 8.4%. For BRCA1 mutation carriers, increased risks were noted for gastric, hepatobiliary, renal, and testis cancers, as well as leukemia. For BRCA2 mutation carriers, increased risks of prostate and pancreas cancers were described. The estimated carrier frequency for combined BRCA1 and BRCA2 mutations was estimated as 1 in 100 in the Ontario population.
For the most part, the findings of this study that were derived from direct measurement confirm previous studies, whereas other estimates derived from indirect measurements vary somewhat from the literature. For example, the estimate of the proportion of ovarian cancers attributable to BRCA mutations is fully consistent with previous estimates of approximately 10% (in contrast to the Ashkenazi subset of case patients with BRCA-linked ovarian cancer, in which the proportion is four times higher), and the associations of cancer risks according to position of the mutation within the BRCA2 gene are consistent with previous reports (14).
In contrast, the estimates of the associated cancers and frequency of BRCA mutations from Risch et al. reflect the strengths and the limitations of their study design. Because there was no confirmation of the pathology of cancers reported by family history, the spectrum of cancer risks reported share the potential biases of previous self-report studies (15–17). The penetrance estimates of this report are also limited by sample design. The case proband or genotyped affected proband approach (1,18) used by Risch et al. was also population based, with the index case patients selected without regard to family history of other factors (19). Even such population-based designs remain vulnerable to bias because of partial participation, as reflected by the fact that half of eligible case patients could not be included in the study. In contrast to hospital-based and volunteer case proband series, population-based ascertainments have generally resulted in lower age-specific penetrance estimates for BRCA-associated breast cancer (Fig. 1). However, one of the notable aspects of the study by Risch et al. is the 90% breast cancer risk by age 80 years estimated for BRCA1 mutation carriers, the highest yet reported for a population-based study (Fig. 1). However, the estimate for ovarian cancer risks for BRCA2 mutation carriers in the study by Risch et al. is among the lowest reported. A recent study that used a retrospective likelihood approach to correct for bias that was induced by oversampling of participants with a positive family history resulted in risk estimates similar to those obtained in the population-based approaches (31). Explanations for the differences in risk estimates among these studies include the biases in case patient (and control subject) selection because of selective participation or other methodologic factors (1–9), differing environmental or other modifying genetic factors, and genotype–phenotype associations that impact on kindreds segregating BRCA mutations.
|
Perhaps the most robust method to measure cancer risks in BRCA mutation carriers has come from follow-up of ongoing prospective cohort studies. Two such prospective series (37,38) have provided an estimate of the risk of breast cancer for BRCA1 mutation–positive individuals: each study has found an annual risk of 2.5%. This value is within the range derived from linkage studies and the estimates obtained by Risch et al.
Among the most provocative findings of the study by Risch et al. is the very high frequency of BRCA mutations estimated in this population: 1 in 100 compared with previous estimates of approximately 1 in 800. The estimates by Risch et al. were imputed on the basis of mutation frequency in case patients and not measured directly in control subjects. In addition, the case population included some subjects from groups (e.g., Ashkenazi Jews and French Canadians) that are known to harbor common founder mutations. Nonetheless, this relatively high estimate of BRCA mutation frequency requires confirmation by other population series because it will impact penetrances that are estimated by other designs (36).
Finally, it should be emphasized, as Risch et al. themselves remind us, that the clinical implications of these findings are generally consistent with current practice in clinical cancer genetics. Although somewhat lower than previous estimates, the ovarian cancer penetrance rate associated with BRCA2 mutations in this report still warrants consideration of risk-reducing surgery, albeit at a somewhat older age than that recommended for BRCA1 mutation carriers. Although penetrance estimates continue to vary between studies, BRCA mutation status remains one of the strongest markers for risk of this disease, warranting increased surveillance with such modalities as magnetic resonance imaging, hormonal and other chemoprevention, and, in selected circumstances, preventive surgery (10,11,39).
NOTES
Supported in part by the Weissenbach, Southworth, Niehaus Foundation.
REFERENCES
(1) Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221–6.
(2) Amos CR. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:74–5.
(3) Risch H, Narod S. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:73–4.
(4) Pharoah PP, Antoniou A, Hopper J, Easton D. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:75–6.
(5) Whittemore AS, Gong G. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:76–7.
(6) Burke W, Austin MA. Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003;95:78–9.
(7) Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PDP, Whittemore AS. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2187–8.[Medline]
(8) Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2188.
(9) King MC; New York Breast Cancer Study Group. Re: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2188–91.
(10) Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276–92.
(11) Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656–63.
(12) Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin–cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694–706.
(13) Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700–10.[CrossRef][Web of Science][Medline]
(14) Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410–9.[CrossRef][Web of Science][Medline]
(15) Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. J Natl Cancer Inst 2002;94:1358–65.
(16) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310–6.
(17) Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365–72.
(18) Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998;148:623–30.
(19) Hopper JL, Bishop DT, Easton DF. Population-based family studies in genetic epidemiology. Lancet 2005;366:1397–406.[CrossRef][Web of Science][Medline]
(20) Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692–5.[CrossRef][Web of Science][Medline]
(21) Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265–71.[Web of Science][Medline]
(22) Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, et al. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004;12:899–906.[CrossRef][Web of Science][Medline]
(23) Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496–504.[Web of Science][Medline]
(24) Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, et al. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 2005;43:404–13.[CrossRef][Web of Science][Medline]
(25) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000;83:1301–8.[CrossRef][Web of Science][Medline]
(26) Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101–2.[CrossRef][Web of Science][Medline]
(27) King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6.
(28) Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30.[CrossRef][Web of Science][Medline]
(29) Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241–7.
(30) Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467–73.
(31) Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863–71.
(32) Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–8.
(33) Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741–7.
(34) Easton DF, Steele L, Fields P, Ormiston W, Averil D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120–8.[Web of Science][Medline]
(35) Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337–9.[CrossRef][Web of Science][Medline]
(36) Offit K, Thom P. Cancer risks in BRCA1 and BRCA2 mutation carriers. In: Rebbeck T, Isaacs C, editors. Hereditary breast cancer. Informa. In press 2007.
(37) Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15.
(38) Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159–64.
(39) Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. JAMA 2004;292:1368–70.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Raskin, F. Lejbkowicz, O. Barnett-Griness, S. Dishon, R. Almog, and G. Rennert BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1617 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma J. Clin. Oncol., January 20, 2009; 27(3): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Offit and J. E. Garber Time to Check CHEK2 in Families With Breast Cancer? J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Robson and K. Offit Management of an Inherited Predisposition to Breast Cancer N. Engl. J. Med., July 12, 2007; 357(2): 154 - 162. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||